Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1057751 | 0.97 | — | — | |
| SCHEMBL1309714 | 0.97 | — | — | |
| SCHEMBL7638521 | 0.97 | EPHX1 (0.55) | EPHX1LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL19574718 | 0.97 | EPHX1 (0.55) | EPHX1LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL1924117 | 0.97 | EPHX1 (0.55) | EPHX1LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL7639464 | 0.97 | EPHX1 (0.55) | EPHX1LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL7637097 | 0.97 | EPHX1 (0.55) | EPHX1LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL9801180 | 0.97 | EPHX1 (0.55) | EPHX1LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL9801630 | 0.97 | EPHX1 (0.55) | EPHX1LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL9801057 | 0.97 | EPHX1 (0.55) | EPHX1LMNAALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| CN-101282949-B | Azole and thiazole derivatives and uses thereof | ARGENTA DISCOVERY LTD | 2012-05-23 | — | — | CN | disclosed |
| EP-2280006-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION COMPRISING AN OXAZOLE OR THIAZOLE M3 MUSCARINIC RECEPTOR ANTAGONIST | Pulmagen Therapeutics (Synergy) Limited (GB) | 2011-02-02 | — | — | EP | disclosed |
| EP-1924570-B1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS SYNERGY (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| CN-101282949-A | Azole and thiazole derivatives and their use | ARGENTA DISCOVERY LTD (GB) | 2008-10-08 | — | — | CN | disclosed |
| EP-1924570-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | Argenta Discovery Limited (GB) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008017827-A2 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LIMITED (GB) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007017669-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | CHRM3, CHRM2, CHRM1 | SIGMAR1 97/4885EPHX1 2280/4885LMNA 3305/4885 |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | CHRM3, GPR65, GPR34 | SIGMAR1 633/4885EPHX1 3047/4885LMNA 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.